1 / 6

Anti-hypertensive Therapeutics in APAC Markets Deals and Strategic Consolidations to 2021

Hypertension is a chronic medical condition characterized by elevated blood pressure in the arteries. It affected an estimated 517 million people in 2014, a figure that will grow at a Compound Annual Growth Rate (CAGR) of 1.2% to 561 million in 2021 in the four Asia-Pacific (APAC) regions of China, India, Australia, and Japan. This high prevalence is a substantial contributor to healthcare costs and a major cause of morbidity. Despite this, awareness of hypertension is low among physicians, patients, and the public alike, leading to poor blood pressure control

jack2222simon
Download Presentation

Anti-hypertensive Therapeutics in APAC Markets Deals and Strategic Consolidations to 2021

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline By RnRMarketResearch.com Publisher Name : GBI Research Date: 01-Jul-2015 No. of pages: 82 Single User License: US $4995 Browse more Reports on Hypertension Drugs at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/hypertension-drugs . ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  2. Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline Hypertension is a chronic medical condition characterized by elevated blood pressure in the arteries. It affected an estimated 517 million people in 2014, a figure that will grow at a Compound Annual Growth Rate (CAGR) of 1.2% to 561 million in 2021 in the four Asia-Pacific (APAC) regions of China, India, Australia, and Japan. This high prevalence is a substantial contributor to healthcare costs and a major cause of morbidity. Despite this, awareness of hypertension is low among physicians, patients, and the public alike, leading to poor blood pressure control. The classes of drugs prescribed to treat hypertension are Angiotensin Converting Enzyme Inhibitors (ACEI), Angiotensin Receptor Blockers (ARB), Calcium Channel Blockers (CCB), beta-blockers, renin inhibitors, and diuretics. The percentage of patients treated using monotherapy and combination therapy (including fixed-dose combinations) varies from country to country. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  3. Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline Products Discussed/Mentioned in this Research: Prestalia (perindopril arginine + amlodipine besylate), Azilva (azilsartanmedoxomil), Amlodipine besylate, Telmisartan, Aliskiren, Olmesartanmedoxomil, Valsartan, Losartan 31 and Exforge (amlodipine + valsartan) Explore More Research Report on Hypertension Drugs Market. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  4. Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline Scope For Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021 • Hypertension prevalence is a prominent contributor to market size in the assessed countries. The market is mostly dominated by generics, and there are only a few patented products. • Will generics continue to dominate treatment? • How do the elderly populations and their associated risk factors affect prevalence? • The current anti-hypertensive therapeutics pipeline is weak, comprising 124 molecules in various stages of development, dominated by small molecules. • Will the upcoming molecules change the treatment paradigm in the near future? • How will the weak pipeline affect the market? • Analysis of clinical trials since 2006 identified that anti-hypertensive products have a high rate of attrition. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  5. Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline Reasons to Buy: • Understand the clinical context of hypertension by considering symptoms, etiology, pathophysiology, co-morbidities and complications, epidemiology, diagnosis, and treatment options. • Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape, and recognize gaps. • Appreciate key anti-hypertensive pipeline trends in molecule type, administration route, mechanism of action, and novelty. • Consider market opportunities and potential risks by examining trends in anti-hypertensive clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action. • Compare treatment usage patterns, annual therapy costs, and market growth projections for the China, India, Australia, and Japan. • Discover trends in licensing and co-development deals concerning anti-hypertensive products and identify the major strategic consolidations that have shaped the commercial landscape. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  6. Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline For more details contact Mr. Ritesh Tiwari :sales@rnrmarketresearch.com/ +18883915441 RnRMarkertResearch RnRMarketResearch.com, an online repository of market  research reports, offers in-depth analysis of over 5000 market segments. RnRMarket Research library has syndicated reports by leading market research  publishers across the globe. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

More Related